TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Short-Form 36 physical Function (PF) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: BETY-Biopsychosocial Questionnaire (BETY-BQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 24-hour pad test weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficult intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Half-life (t1/2λz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable Glasgow Outcome Score-Extended (GOS-E)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BIRADS Breast Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological response (HCV RNA non detectable at W28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: functional success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and grade of biopsy-proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Participants With at Least One (≥1) COVID-19-related Hospitalization or All-cause Death (Ph3 Cohort 1- 1.2g vs Placebo)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Participants With at Least One (≥1) COVID-19-related Hospitalization or All-cause Death (Ph3 Cohort 1 - 2.4g vs Placebo)
Endpoint domain: Mortality/survival
Primary endpoint: Ischemia-driven Target Lesion Failure (TLF)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Fecal Calprotectin Less Than 150 Microgram/Gram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: paraoxonase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of remifentanil during the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration to achieve full enteral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum zonulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of bilateral adrenal sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ratings of child EF difficulties interference with daily functioning
Endpoint domain: Life impact
Endpoint subdomain: Functional functioning
Primary endpoint: Quality of Spine Fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Spine Fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the concentration curve (AUC) to anti-tuberculosis medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of adverse events/serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction on risk factors for cardiovascular diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subject's in NYHA Functional Class I or II at 8 Year Post-Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subject's New York Heart Association (NYHA) Functional Class at 8 Years Post-Implant Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in hematologic support score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inventory of Drug Use Consequences (InDuC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of individuals attending calls
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percent of subjects with orgasm dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in HAMD-17 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of Ethinylestradiol in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of Levonorgestrel in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of Ethinylestradiol in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of Levonorgestrel in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of subjects in clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of subjects who respond to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction rate in memory association recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of characteristic MS-like lesions on baseline MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of Participants Achieving Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Healthy tooth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOWA Conners Inattention/Overactivity subscale ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite Z-score of Pain-anxiety-depression Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: calculated total blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total seconds of FOG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL10 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gastrointestinal Symptom Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Hydrogen Breath Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Renal function assessed by calculated creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Plasma Concentration Measure of Indoxyl Sulphate (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Plasma Concentration Measure P-Cresyl Sulphate (PCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total CD34+ cell yield on the first apheresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobilization failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgM/IgG titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peripheral blood T cells specific to different SARS-CoV-2 proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Primary or repeated COVID-19 cases
Endpoint domain: Adverse events/effects
Primary endpoint: score on a measure of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: score on a measure of independent living skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Patients Experiencing Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Who Have a Best Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ki-67 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient assessment of pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: number of participants with KLH and/or tumor-specific antigens immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in total gastric volume (TGV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of graft-versus-host disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of veno-occlusive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of thrombotic microangiopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vitamin D sufficiency following Stoss dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean difference in pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Deficit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decrease in PRA Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: number of lung cancer diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of stage I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: rate of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: rate of false positive
Endpoint domain: Adverse events/effects
Primary endpoint: International Restless Legs Syndrome Study Group Rating Scale (IRLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Commitment check
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Change from baseline in Vascular Engorgement in 1% HY02 Ointment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline in Eye Discomfort Visual Analogue Score (VAS) in 1% HY02 Ointment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality (subjective)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality (objective)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Solicited Local Reactions Based on the Functional Grading Scale After the First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants in the 18-64 Year Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 8-10 Days Following 1 Dose of Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of progression of bone maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adherence to program delivery protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PWT change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDS TBR change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesser prevalence of comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehension of transplant procedures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: level of maternal worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mother-sibling interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: internalizing and externalizing behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: staining of the cornea and conjunctiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom frequency score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bleeding on probing (BoP) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Median Progression-free Survival (6-month PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Symmetry of lateral laparoscopic ports
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adverse events based on frequency, causality, and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Study drug concentrations to characterize pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total thiobarbituric acid reactive substances (TBARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-motor aspects of Parkinson's Disease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline of the Ocular Surface Disease Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with HIV RNA<50 Copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety determined by a Neonatal Infant Pain Scale (NIPS) score
Endpoint domain: Adverse events/effects
Primary endpoint: Efficiency determined by an Efficiency of Loss scale
Endpoint domain: Resource use
Primary endpoint: Maximum Tolerated Dose (MTD) determined by dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: neural response to food odor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent total weight loss (%TWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent BMI loss (%BMIL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of duloxetine versus placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta SOFA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle and bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Aerobic power (oxygen consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Intensity of Suicidal Ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Severity of Depression Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in augmentation indices (augmentation index and heart rate-corrected augmentation index (AIx@75))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of all-cause death, recurrent myocardial infarction, stroke, and bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of bleeding complication
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of thrombotic complications requiring intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Functional Residual Capacity (FRC) variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Right ventricular systolic and diastolic functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Participants With HBeAg Loss and HBV DNA ≤1,000 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events (AEs) Per Person-Year of Observation
Endpoint domain: Adverse events/effects
Primary endpoint: Psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PASAT-3 score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: proportion of brain gray matter volume to intracranial volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Types of forms of Kimmerle anomaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure-Free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of admissions to the Emergency Department
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Logarithmic Energy Entropy values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prosthetic survival
Endpoint domain: Mortality/survival
Primary endpoint: Degree of hair regrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's perception of pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amount of opioids needed to control pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of Wnt signaling pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Reactogenicity Per Subject and Treatment Group
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of rNV-2v
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of rNV-2v
Endpoint domain: Adverse events/effects
Primary endpoint: Reactogenicity of rNV-2v
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any TEAE, by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CLDEQ-8 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lisamine staining scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Discussion rates
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Primary postpartum haemorrhage from atony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: D5-phenylalanine appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Numeric Rating Scale (PNRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of plasma AMH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient Global Impression of Severity (PGI-S) Respiratory Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PGI-S Fatigue Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory Symptoms Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-Reported Outcome Measurement Information System - Fatigue-Short Form 7a (PROMIS F-SF 7a) Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Recurrence of Brain Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline on extinction-induced functional MRI responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cancer-Related Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Pulpal Anesthesia Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Objective sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carboxy-hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fatty acids lipidomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aldosterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Tolerability of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety assessed by laboratory tests and clinical Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: development of RDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of parturients with pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of mucosa inspected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about Keloid Scars
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of ≥grade 3 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of pro-NT BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Management of acute pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major amputation free survival
Endpoint domain: Mortality/survival
Primary endpoint: Cervical cancer screening effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes